Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sava

Showing results (151-160 of 194) with videos related to

Pageof 20
Sort By:
Dalton Transactions (Cambridge, England : 2003)|December 10, 2014
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activityV Novohradský, A Bergamo, M Cocchietto, et al.
Die Pharmazie|October 1, 1990
Kinetic investigation of the aqueous stability and antitumor activity of a hydrosoluble diaryltriazene, AVIS, related to the antimetastatic agent DM-COOKL Lassiani, C Ebert, C Nisi, et al.
Anticancer Research|September 1, 1996
Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinomaS Pacor, E Giacomello, A Bergamo, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOKG Sava, S Zorzet, L Perissin, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 1999
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatinA Bergamo, R Gagliardi, V Scarcia, et al.
Journal of Inorganic Biochemistry|June 1, 2000
Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigationE Alessio, E Iengo, S Zorzet, et al.
Metal-Based Drugs|January 1, 1995
Efficacy of 5-FU Combined to Na[trans-RuCl(4)(DMSO)Im], A Novel Selective Antimetastatic Agent, on the Survival Time of Mice With P388 Leukemia, P388/DDP subline and MCa Mammary CarcinomaM Coluccia, G Sava, G Salerno, et al.
Diabetes & Metabolism|October 18, 2008
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathyM Cocchietto, L Zorzin, B Toffoli, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 8, 2004
Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cellsF Frausin, V Scarcia, M Cocchietto, et al.
Metal-Based Drugs|January 1, 1996
Reduction of Lung Metastases by Na[trans-RuCl(4)(DMSO)Im] is not Coupled With the Induction of Chemical XenogenizationG Sava, G Salerno, A Bergamo, et al.
Pageof 20

Showing results (151-160 of 194) with videos related to

Sort By:
Pageof 20
Dalton Transactions (Cambridge, England : 2003)|December 10, 2014
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activityV Novohradský, A Bergamo, M Cocchietto, et al.
Die Pharmazie|October 1, 1990
Kinetic investigation of the aqueous stability and antitumor activity of a hydrosoluble diaryltriazene, AVIS, related to the antimetastatic agent DM-COOKL Lassiani, C Ebert, C Nisi, et al.
Anticancer Research|September 1, 1996
Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinomaS Pacor, E Giacomello, A Bergamo, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOKG Sava, S Zorzet, L Perissin, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 1999
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatinA Bergamo, R Gagliardi, V Scarcia, et al.
Journal of Inorganic Biochemistry|June 1, 2000
Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigationE Alessio, E Iengo, S Zorzet, et al.
Metal-Based Drugs|January 1, 1995
Efficacy of 5-FU Combined to Na[trans-RuCl(4)(DMSO)Im], A Novel Selective Antimetastatic Agent, on the Survival Time of Mice With P388 Leukemia, P388/DDP subline and MCa Mammary CarcinomaM Coluccia, G Sava, G Salerno, et al.
Diabetes & Metabolism|October 18, 2008
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathyM Cocchietto, L Zorzin, B Toffoli, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 8, 2004
Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cellsF Frausin, V Scarcia, M Cocchietto, et al.
Metal-Based Drugs|January 1, 1996
Reduction of Lung Metastases by Na[trans-RuCl(4)(DMSO)Im] is not Coupled With the Induction of Chemical XenogenizationG Sava, G Salerno, A Bergamo, et al.
Pageof 20